GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Price-to-Free-Cash-Flow

InnoCare Pharma (HKSE:09969) Price-to-Free-Cash-Flow : N/A (As of May. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Price-to-Free-Cash-Flow?

As of today (2024-05-12), InnoCare Pharma's share price is HK$5.10. InnoCare Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Hence, InnoCare Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for InnoCare Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:09969's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.585
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

InnoCare Pharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was HK$0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -5.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -50.80% per year.

During the past 7 years, InnoCare Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 51.00% per year. The lowest was -121.10% per year. And the median was -38.65% per year.


InnoCare Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for InnoCare Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Price-to-Free-Cash-Flow Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InnoCare Pharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, InnoCare Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Price-to-Free-Cash-Flow falls into.



InnoCare Pharma Price-to-Free-Cash-Flow Calculation

InnoCare Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=5.10/0
=N/A

InnoCare Pharma's Share Price of today is HK$5.10.
InnoCare Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

InnoCare Pharma  (HKSE:09969) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


InnoCare Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines